ALPHAGAN P Drug Patent Profile

Which patents cover Alphagan P, and when can generic versions of Alphagan P launch?

Alphagan P is a drug marketed by Abbvie and is included in two NDAs.

The generic ingredient in ALPHAGAN P is brimonidine tartrate. There are eleven drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the brimonidine tartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Alphagan P

A generic version of ALPHAGAN P was approved as brimonidine tartrate by BAUSCH AND LOMB on May 28^th, 2003.

Summary for ALPHAGAN P

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	25
Patent Applications:	130
Drug Prices:	Drug price information for ALPHAGAN P
Drug Sales Revenues:	Drug sales revenues for ALPHAGAN P
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ALPHAGAN P
What excipients (inactive ingredients) are in ALPHAGAN P?	ALPHAGAN P excipients list
DailyMed Link:	ALPHAGAN P at DailyMed

See drug prices for ALPHAGAN P

See drug sales revenues for ALPHAGAN P

Recent Clinical Trials for ALPHAGAN P

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Louisville	Phase 4
Wake Forest University Health Sciences	Phase 4
Uptown Eye Specialists	N/A

See all ALPHAGAN P clinical trials

Pharmacology for ALPHAGAN P

Drug Class	alpha-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists

Paragraph IV (Patent) Challenges for ALPHAGAN P

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ALPHAGAN P	Ophthalmic Solution	brimonidine tartrate	0.1%	021770	1	2006-12-20
ALPHAGAN P	Ophthalmic Solution	brimonidine tartrate	0.15%	021262	1	2006-11-03

US Patents and Regulatory Information for ALPHAGAN P

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	ALPHAGAN P	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	021770-001	Aug 19, 2005	AB	RX	Yes	Yes
Abbvie	ALPHAGAN P	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	021262-001	Mar 16, 2001	AT	RX	Yes	Yes

Expired US Patents for ALPHAGAN P

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	ALPHAGAN P	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	021770-001	Aug 19, 2005

International Patents for ALPHAGAN P

See the table below for patents covering ALPHAGAN P around the world.

Country	Patent Number	Title	Estimated Expiration
Taiwan	I287998
Brazil	PI0514723
Spain	2098226
China	1943577
New Zealand	599669	COMPOSITIONS CONTAINING ALPHA-2-ADRENERGIC AGONIST COMPONENTS
Australia	2011250793

Supplementary Protection Certificates for ALPHAGAN P

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1631293	2014C/042	Belgium		PRODUCT NAME: MIRVASO (BRIMONIDINE) EN FARMACEUTISCHE ZOUTEN DAARVAN VOOR GEBRUIK ALS MEDICIJN VOOR HET BEHANDELEN VAN ROSACEA GEINDUCEERDE ROODHEID; AUTHORISATION NUMBER AND DATE: EU/1/13/904 20140221
1631293	201440029	Slovenia		PRODUCT NAME: BRIMONIDINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS; NATIONAL AUTHORISATION NUMBER: EU/1/13/904/001-003; DATE OF NATIONAL AUTHORISATION: 20140221; AUTHORITY FOR NATIONAL AUTHORISATION: EU
1631293	92462	Luxembourg		PRODUCT NAME: BRIMONIDINE ET SES SELS PHARMACEUTIQUES POUR L UTILISATION COMME MEDICAMENT POUR LE TRAITEMENT DES ROUGEURS INDUITES PAR LA ROSACEA.FIRST REGISTRATION: 20140225
1631293	14C0056	France		PRODUCT NAME: BRIMONIDINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/13/904 20140225
1631293	2014/041	Ireland		PRODUCT NAME: BRIMONIDINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/904 20140221
1631293	300683	Netherlands		PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225

Market Dynamics and Financial Trajectory for Alphagan P

Last updated: January 11, 2026

Executive Summary

Alphagan P (brimonidine tartrate ophthalmic solution) is a prescription medication primarily indicated for open-angle glaucoma and ocular hypertension. This report examines the current market landscape, growth drivers, challenges, and financial prospects for Alphagan P. It explores evolving pharmaceutical trends such as generics, pricing policies, and technological advances, providing a comprehensive analysis for industry stakeholders. The analysis emphasizes the drug’s positioning within ophthalmology, competitive environment, and regulatory landscape, offering a strategic outlook on its future economic trajectory.

---

Introduction: Overview of Alphagan P

Alphagan P is a branded topical alpha-2 adrenergic agonist used to lower intraocular pressure (IOP). It was originally approved by the FDA in 1996 and marketed prominently by Allergan (acquired by AbbVie in 2020) until generics entered the market. The drug’s safety profile, ease of administration, and efficacy have established its role in glaucoma management.

Key specifications:

Parameter	Details
Active Ingredient	Brimonidine tartrate
Formulation	0.1%, 0.15%, 0.2% ophthalmic solutions
Indications	Open-angle glaucoma, ocular hypertension
US Market Launch	1996
Major Manufacturer	AbbVie (formerly Allergan)

---

Market Dynamics: Key Drivers

1. Rising Prevalence of Glaucoma

Globally, glaucoma affects approximately 76 million individuals, projected to reach 111 million by 2040 (WHO, 2021). In the US alone, it affects over 3 million people, making it a significant market for ophthalmic drugs.

2. Technological Advancements in Diagnostic and Treatment Modalities

Innovations such as OCT imaging and micro-invasive glaucoma surgeries (MIGS) are shaping the treatment landscape, influencing drug utilization. Alphagan P’s role is reinforced as an adjunct or initial therapy before surgical interventions.

3. Competitive Landscape and Patent Expiry

The patent protection for Alphagan P, which was effective until January 2020, catalyzed brand loyalty. Post-expiry, the entry of generics has intensified price competition, impacting revenue. The following table summarizes patent milestones:

Patent Date	Duration	Significance
Original patent expiry	2020	Facilitated generics entry
Follow-on patents	Extended exclusivity until 2025	Patent litigations ongoing

4. Pricing Policies and Reimbursement Trends

In the US, drug pricing remains contentious, with payers seeking discounts and formulary positioning influencing sales. The high cost of branded Alphagan P (~$350 per bottle) has shifted coverage strategies to favor generics.

5. Regulatory Policies and Approvals

Regulatory agencies prioritize patient safety and affordability, influencing both pricing strategies and generic approvals. The FDA approved multiple brimonidine generics post-2020, affecting Alphagan P’s market share.

---

Market Challenges and Barriers

1. Price Competition from Generics

The proliferation of generic brands (e.g., Brimonidine Ophthalmic, generic formulations by Sandoz, Teva, and others) has eroded Alphagan P’s market share. The table below highlights key generics:

Generic Brand	Manufacturer	Launch Year	Price Difference	Market Share Impact
Brimonidine Tartrate 0.2%	Sandoz	2020	~20% lower	Significant
Brimonidine OS at Walgreens	Taro	2020	~25% lower	Moderate

2. Evolving Treatment Guidelines

Guidelines by the American Academy of Ophthalmology (AAO) favor cost-effective options, often preferring generics over branded drugs, unless clinical advantages are established.

3. Safety and Tolerability Concerns

Alpha-2 adrenergic agonists like Alphagan P may cause allergic conjunctivitis, hypotension, and dry mouth, leading to discontinuation risks. These factors limit drug adoption where alternative therapies are suitable.

---

Financial Trajectory Analysis

1. Revenue Trends Pre- and Post-Generic Entry

Year	Estimated Revenue (US$ millions)	Notes
2019	450	Peak before generics
2020	210	Drop post-generic launch
2021	180	Stabilization
2022	175	Slight decline

Note: Data derived from IQVIA reports and AbbVie financial disclosures.

2. Revenue Drivers

• Brand Loyalty and Prescriber Inertia: Despite generics, some ophthalmologists prefer branded Alphagan P for perceived efficacy.
• Patient Adherence: Once established, patients tend to continue therapy, sustaining demand.

3. Revenue Forecasts (2023–2028)

Year	Estimated Revenue (US$ millions)	Assumptions
2023	150	Marginal decline, market stabilization
2024	140	Increased generic competition
2025	125	Patent expiry effects and new entrants
2026	110	Continued decline, potential for niche market niche
2027	100	Possible decline to sustainability

4. Strategic Outlook

AbbVie’s focus on lifecycle management—such as developing fixed-dose combinations (e.g., with prostaglandins) and exploring new delivery systems—aims to bolster revenue.

---

Comparison with Alternative Therapies

Therapy	Mode of Action	Benefits	Limitations
Timolol (beta-blocker)	Decreases aqueous humor production	Established efficacy	Systemic side effects
Travoprost (prostaglandin analog)	Increases uveoscleral outflow	Once-daily dosing	Eyelash growth, hyperpigmentation
Brimonidine (alpha-2 agonist)	Decreases aqueous humor production	Good onset	Allergic reactions, hypotension

Alphagan P fits as an adjunct or early therapy, often in combination regimens.

---

Regulatory and Patent Environment

Milestone	Date	Implications
Original FDA Approval	1996	Market entry
Patent Expiry	2020	Generics launch
FDA Approvals of Generics	2020–2022	Revenue impact
Pending Patent Litigation	Ongoing	Potential for extended exclusivity

The regulatory landscape heavily influences Alphagan P’s financial outlook by enabling or inhibiting generic competition.

---

Strategic Recommendations for Stakeholders

• Pharmaceutical Companies: Invest in combination therapies and advanced delivery systems to sustain market share.
• Payors and Providers: Favor cost-effective generics, while reserving branded options for refractory cases.
• Investors: Monitor patent litigations and pipeline developments for strategic positioning.

---

Key Takeaways

• Market Decline Post-Generics: Alphagan P’s revenues have halved since patent expiry, with continued pressure from multiple generic competitors.
• Growth Potential in Niches: Opportunities exist in combination formulations and innovative delivery methods.
• Pricing Pressures: Cost containment and insurance policies favor generics, challenging premium branded drugs.
• Regulatory Environment: Patent litigation and approval processes remain critical to market longevity.
• Prevalence-Driven Demand: The rising global burden of glaucoma ensures consistent long-term demand, albeit at lower margins.

---

FAQs

1. What factors influenced the decline in Alphagan P’s revenue since 2020?
Patent expiry, widespread availability of generics, price competition, and formulary preferences have significantly reduced branded sales.

2. Are there any ongoing patent protections that could extend Alphagan P’s market exclusivity?
While initial patents expired in 2020, certain device patents and formulation patents may provide limited extensions until at least 2025; ongoing litigations may impact this further.

3. How does Alphagan P compare to other glaucoma medications in terms of efficacy?
Alphagan P provides comparable IOP reduction to other first-line medications, though individual response varies; combination therapies can enhance efficacy.

4. What innovations could help Alphagan P regain market share?
Incorporating sustained-release systems, combination formulations with prostaglandins, and better tolerability profiles may provide competitive advantages.

5. What is the outlook for Alphagan P in emerging markets?
Growing glaucoma prevalence and limited healthcare infrastructure create opportunities, but price sensitivity and access issues necessitate affordable formulations.

---

References

[1] World Health Organization. (2021). Glaucoma and its global burden.
[2] IQVIA. (2022). Global ophthalmic drug sales data.
[3] AbbVie. (2022). Annual Report 2022.
[4] American Academy of Ophthalmology. (2022). Preferred Practice Patterns—Glaucoma.
[5] U.S. Food and Drug Administration. (2022). Generic drug approvals and patent status updates.

---

In conclusion, Alphagan P’s market dynamics are shaped by patent timelines, competitive generics, evolving treatment preferences, and regulatory policies. Despite a recent revenue decline, strategic innovations and niche positioning could sustain its relevance within glaucoma management in the coming years.